Issue 67, 2021

Iridium(iii) complexes as mitochondrial topoisomerase inhibitors against cisplatin-resistant cancer cells

Abstract

Herein, we developed the first metal-based mitochondrial topoisomerase inhibitors to achieve an effective therapeutic outcome for the therapy of cisplatin-resistant tumour cells.

Graphical abstract: Iridium(iii) complexes as mitochondrial topoisomerase inhibitors against cisplatin-resistant cancer cells

Supplementary files

Article information

Article type
Communication
Submitted
24 Apr 2021
Accepted
21 Jul 2021
First published
21 Jul 2021

Chem. Commun., 2021,57, 8308-8311

Iridium(III) complexes as mitochondrial topoisomerase inhibitors against cisplatin-resistant cancer cells

L. He, K. Xiong, L. Wang, R. Guan, Y. Chen, L. Ji and H. Chao, Chem. Commun., 2021, 57, 8308 DOI: 10.1039/D1CC02178H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements